When the good and bad bacteria in our mouth become imbalanced, the bad bacteria form a biofilm (aka plaque), which can cause cavities, and if left untreated over time, can lead to cardiovascular and other inflammatory diseases like diabetes and bacterial pneumonia.
A team of researchers from the University of Illinois has recently devised a practical nanotechnology-based method for detecting and treating the harmful bacteria that cause plaque and lead to tooth decay and other detrimental conditions.
Oral plaque is invisible to the eye so dentists currently visualize it with disclosing agents, which they administer to patients in the form of a dissolvable tablet or brush-on swab. While useful in helping patients see the extent of their plaque, these methods are unable to identify the difference between good and bad bacteria.
“Presently in the clinic, detection of dental plaque is highly subjective and only depends on the dentist’s visual evaluation,” said Bioengineering Associate Professor Dipanjan Pan, head of the research team. “We have demonstrated for the first time that early detection of dental plaque in the clinic is possible using the regular intraoral X-ray machine which can seek out harmful bacteria populations.”
In order to accomplish this, Fatemeh Ostadhossein, a Bioengineering graduate student in Pan’s group, developed a plaque detection probe that works in conjunction with common X-ray technology and which is capable of finding specific harmful bacteria known as Streptococcus mutans (S. mutans) in a complex biofilm network. Additionally, they also demonstrated that by tweaking the chemical composition of the probe, it can be used to target and destroy the S. mutans bacteria.
The probe is comprised of nanoparticles made of hafnium oxide (HfO2), a non-toxic metal that is currently under clinical trial for internal use in humans. In their study, the team demonstrated the efficacy of the probe to identify biochemical markers present at the surface of the bacterial biofilm and simultaneously destroy S. mutans. They conducted their study on Sprague Dawley rats.
In practice, Pan envisions a dentist applying the probe on the patient’s teeth and using the X-ray machine to accurately visualize the extent of the biofilm plaque. If the plaque is deemed severe, then the dentist would follow up with the administering of the therapeutic HfO2 nanoparticles in the form of a dental paste.
In their study, the team compared the therapeutic ability of their nanoparticles with Chlorhexidine, a chemical currently used by dentists to eradicate biofilm. “Our HfO2nanoparticles are far more efficient at killing the bacteria and reducing the biofilm burden both in cell cultures of bacteria and in [infected] rats,” said Ostadhossein, noting that their new technology is also much safer than conventional treatment.
The nanoparticles’ therapeutic effect is due, said Pan, to their unique surface chemistry, which provides a latch and kill mechanism. “This mechanism sets our work apart from previously pursued nanoparticle-based approaches where the medicinal effect comes from anti-biotics encapsulated in the particles,” said Pan, also a faculty member of the Carle Illinois College of Medicine and the Beckman Institute for Advanced Science and Technology. “This is good because our approach avoids anti-biotic resistance issues and it’s safe and highly scalable, making it well-suited for eventual clinical translation.”
The Latest on: Oral plaque
via Google News
The Latest on: Oral plaque
- Global Oral Care Products Market, Market players, Market Research, Growth During to 2016-2022on October 15, 2019 at 5:13 am
The reason being that the geriatric population are more vulnerable to oral diseases. The rising awareness regarding caries, plaque and periodontal diseases. Increasing demand of cosmetic ...
- Life Molecular Imaging announces presentation of new research results at the European Association of Nuclear Medicine 2019 Annual Meetingon October 13, 2019 at 5:00 am
Notable oral presentations comprise: Florbetaben Amyloid-PET Neuroimaging ... imaging of the brain to estimate β-amyloid neuritic plaque density in adult patients with cognitive impairment who are ...
- Lilly Presents Positive Results for Taltz® (ixekizumab) in Pediatric Patients with Moderate to Severe Plaque Psoriasis at theon October 12, 2019 at 3:50 am
Results of the study are being presented as a late-breaking oral presentation at the European Academy of Dermatology and Venereology Congress (EADV) in Madrid, Spain. Based on these positive results, ...
- Can Anticoagulants Prevent Alzheimer's?on October 11, 2019 at 8:24 am
Treatment with an oral anticoagulant delays memory decline and the conversion to Alzheimer disease ... Dabigatran also reduced typical AD symptoms, including cerebral inflammation, blood vessel injury ...
- Association of oral health status with the CD4+ cell count in children living with HIV in Phnom Penh, Cambodiaon October 10, 2019 at 3:07 am
The dentition status of each child was recorded on a WHO oral health assessment form 37. A higher DMFT score indicates a worse dental status. We also examined the presence of dental plaque by staining ...
- AbbVie Announces New Data from its Dermatology Portfolio and Pipeline at the 28th European Academy of Dermatology and Venereology (EADV) Congresson October 8, 2019 at 11:01 pm
In addition, Phase 2b results evaluating time to treatment response with upadacitinib, an oral JAK inhibitor ... is indicated for the treatment of moderate to severe plaque psoriasis in adults who are ...
- An oral anticoagulant delays the appearance of Alzheimer's disease in miceon October 8, 2019 at 6:04 am
This treatment also reduced typical Alzheimer symptoms, including cerebral inflammation, blood vessel injury, and amyloid protein plaques. Population aging is predicted to result ... One goal is to ...
- Lilly to Unveil New Data for the Treatments of Complex Dermatological Conditions at the 28th Annual European Academy of Dermatoon October 8, 2019 at 4:38 am
Taltz Data Oral Presentations Thursday, October 10 o 09:50 ... Placebo-Controlled Study in Pediatric Patients with Moderate-to-Severe Plaque Psoriasis (Presenting author: Kim Papp) Abstract: D3T01.1B ...
- DURECT completes enrollment in mid-stage study of DUR-928 in plaque psoriasison October 7, 2019 at 3:27 pm
DURECT (DRRX-1.3%) has completed enrollment of more than 20 subjects in a Phase 2a clinical trial evaluating topical DUR-928 for the potential treatment of mild-to-moderate plaque psoriasis.
via Bing News